Navigation überspringen
Universitätsbibliothek Heidelberg
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Titel:Chronic myeloid leukemia
Mitwirkende:Hehlmann, Rüdiger [HerausgeberIn]   i
Verf.angabe:edited by Rüdiger Hehlmann
Ausgabe:2nd ed. 2021.
Verlagsort:Cham
 Cham
Verlag:Springer International Publishing
 Imprint: Springer
E-Jahr:2021
Jahr:2021.
 2021.
Umfang:1 Online-Ressource (IX, 273 p. 42 illus., 35 illus. in color.)
Gesamttitel/Reihe:Hematologic Malignancies
 Springer eBook Collection
ISBN:978-3-030-71913-5
Abstract:Cytogenetics of Chronic Myeloid Leukemia (CML) -- The Biology and Pathogenesis of Chronic Myeloid Leukaemia -- Epidemiology of Chronic Myeloid Leukemia.-Imatinib and the first line CML Therapy -- CML Therapy: A Focus on Second and Third Generation Tyrosine Kinase Inhibitors -- Adverse events associated with ATP-competitive BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia -- Pharmacoeconomic considerations for tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia -- Standardization of molecular monitoring for chronic myeloid leukemia: 2021 update -- Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death -- A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia -- The Role of Hematopoietic Stem Cell Transplantation in CML -- CML end-phase and blast crisis: implications and management -- The Interferon-alpha Revival in CML -- Managing Pregnancy in Chronic Myeloid Leukemia -- Response-Related Predictors of Survival and of Treatment Free Remission in CML -- Discontinuation or cessation of tyrosine kinase inhibitor treatment in Chronic myeloid leukemia patients with deep molecular response. .
 This book provides state-of-the-art reviews of key issues and recent developments relating to chronic myeloid leukemia (CML), acquainting the reader with advances in research, treatment, and promotion of public health. Among the management topics addressed are the choices, advantages, and pitfalls of first-, second-, and third-line treatments; the European LeukemiaNet recommendations; management of adverse effects of tyrosine kinase inhibitors (TKI); management of CML blast crisis; management of pregnancy in the context of CML; the role of hematopoietic cell transplantation; the current experience with TKI discontinuation; and the value of interferon α in improving the outcome of TKI treatment. Various aspects of relevance to treatment outcome are discussed, including prognostic scores, molecular monitoring (principles and interlaboratory standardization), and response-related predictors of survival. Furthermore, updates are provided on the increasing prevalence of CML and its implications and on the changing cost of care for CML, taking into account the impact of availability of generic imatinib. .
DOI:doi:10.1007/978-3-030-71913-5
URL:Resolving-System: https://doi.org/10.1007/978-3-030-71913-5
 Cover: https://swbplus.bsz-bw.de/bsz1760110116cov.jpg
 DOI: https://doi.org/10.1007/978-3-030-71913-5
Datenträger:Online-Ressource
Sprache:eng
Bibliogr. Hinweis:Erscheint auch als : Druck-Ausgabe
 Erscheint auch als : Druck-Ausgabe
 Erscheint auch als : Druck-Ausgabe
K10plus-PPN:1760110116
 
 
Lokale URL UB: Zum Volltext
 
 Bibliothek der Medizinischen Fakultät Mannheim der Universität Heidelberg
 Klinikum MA Bestellen/Vormerken für Benutzer des Klinikums Mannheim
Eigene Kennung erforderlich
Bibliothek/Idn:UW / m3936270392
Lokale URL Inst.: Zum Volltext

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/68746386   QR-Code
zum Seitenanfang